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There has been a rapid rise in global probiotic use, but more recently a drop in dairy applications in
Europe, due to regulatory intransigence and rising costs. This review will propose that it is an ideal time
for companies to alter their strategic approach, rather than stop the research and development through
an inability to obtain health claims. Opportunities exist to expand production of dairy probiotics in the
developed and developing world. Data showing effects against diarrhoea, malnutrition, antibiotic side
effects, and their potential to affect allergies and mood, and reduce environmental toxin adsorption,
provide the scientiﬁc basis for shaping a dynamic future for dairy probiotics.
© 2015 The Author. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Contents
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The rapid and impressive rise in the sales of probiotic products
globally has its roots in the launch of dairy probiotic products,
particularly by Yakult, Danone and Valio within the past twenty
years. The emphasis placed by these and a few other companies on
probiotics that were scientiﬁcally and clinically tested, laid the
groundwork for future growth, at least until regulators intervened
in Europe in the mid-2000s. The support for probiotic food led to
the United Nations and World Health Organization assembling an
Expert Panel that in 2001 deﬁned probiotics as “Live microorgan-
isms which when administered in adequate amounts confer aLtd. This is an open access article uhealth beneﬁt on the host” (FAO/WHO, 2001). This deﬁnition has
stood the test of time and been widely adopted by scientiﬁc, in-
dustry and regulatory communities (Hill et al., 2014).
The launch of Activia yoghurt in Canada in 2004 literally
transformed the awareness of probiotic concepts. Within one year,
an estimated 75% of the 8 million people living in Quebec Province
had consumed Activia. This incredible product uptake symbolized
an awakening of the public to a concept that made sense health-
wise, had a scientiﬁc rationale, and had not until then been avail-
able. As advocated in 2008 (Reid, 2008), probiotic foods and sup-
plements tested in human studies have since emerged that convey
local gut and distant site effects on health (Skokovic-Sunjic, 2014).
While market research companies are in the proﬁt-driven
business of projecting the future of probiotic sales, they must rely
on scientiﬁc trends and progress to understand what technologies
and approaches are in the pipeline. This paper will review thisnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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development can be the mediators of making health-promoting
probiotic dairy products reach consumers worldwide.
2. Probiotics for speciﬁc conditions
In almost all cases, dairy probiotics by their nature as a food, are
made available to children and adults all year round. This has
remained despite attributes of probiotic strains showing some
apparently speciﬁc characteristics, such as countering seasonal
allergies (Koyama et al., 2010; Singh et al., 2013), relieving con-
stipation in adults (Agrawal et al., 2009) not children (Tabbers
et al., 2011), reducing drug-associated diarrhoea (de Vrese,
Kristen, Rautenberg, Laue, & Schrezenmeir, 2011), reducing the
duration of acute respiratory infections in otherwise healthy
children and adults (King, Glanville, Sanders, Fitzgerald, & Varley,
2014), reducing anxiety (Messaoudi et al., 2011), and improving
immune parameters in HIV patients (Hemsworth, Hekmat, & Reid,
2012). It raises the question of whether someone not suffering
from any of these issues need take the probiotic? On the one hand,
the clinical effects of these foods are invariably lower than drugs,
for example in lowering cholesterol (Fuentes, Lajo, Carrion, &
Cu~ne, 2013) without the side effects and efﬁcacy levels
compared with statins (Tompkins, Schwartzbard, Gianos, Fisher, &
Weintraub, 2014), yet on the other hand, probiotics can induce
some physiological effects even in a so-called healthy person. For
example, four week consumption of Lactobacillus paracasei subsp.
paracasei LC01 in healthy adults resulted in reduced faecal
Escherichia coli and ammonia, and increases in Lactobacillus, Biﬁ-
dobacterium, and Roseburia intestinalis and acetic and butyric acid
(Zhang et al., 2013).
The ability of some lactobacilli to produce neurochemicals
potentially able to reach the cerebellum via the vagus nerve (Bercik
et al., 2011), raises the question of whether such probiotics could
beneﬁt people with mood disorders? Certainly animal studies have
shown the microbiota gut-brain signalling can be inﬂuenced by
neural, hormonal, immune andmetabolic pathways and potentially
affect mood, pain and cognition (Alcock, Maley, & Aktipis, 2014;
Borre, Moloney, Clarke, Dinan, & Cryan, 2014). But, too often in
science, evidence obtained in mice is presented as meaning the
effects will translate in humans. This is a huge assumption where
anatomy, mechanisms, diet, housing, and so many other factors are
completely different in humans. In one human study that theorized
that disruption of the gut epithelial barrier could lead to inﬂam-
mation and depression, Maes, Kubera, and Leunis (2008) found
higher prevalence of antibodies against enterobacterial lipopoly-
saccharide in patients with major depression than controls. If
probiotic organisms can improve gut barrier resistance, as appears
to be the case in vitro (Resta-Lenert& Barrett, 2003) and in vivo (Liu
et al., 2011), their ingestion might have an effect on mood through
at least this mechanism. Certainly, there is precedent for food
affecting mood, such as ﬁsh and vitamins that increase serotonin, a
mood regulator produced in the brain (Lang & Borgwardt, 2013;
Tanskanen et al., 2001).
In a unique study using magnetic resonance imaging, four week
intake of probiotic yoghurt affected activity of brain regions con-
trolling central processing of emotion and sensation (Tillisch et al.,
2013). Numerous other studies are now underway to explore the
extent of gut microbiota-brain signalling and the degree to which
probiotic foods can inﬂuence it (Mayer, Knight, Mazmanian, Cryan,
& Tillisch, 2014). Of particular interest will be the effect on healthy
controls. Clearly, foods should not adversely affect the mood of
people deemed healthy. In such studies, behavioural outcomes
need to be measured along with gut barrier resistance and where
possible levels of neurochemicals in the bloodstream.Already, some foods are consumed for speciﬁc reasons, such as
high ﬁbre bran for constipation. Perhaps products taken only at
certain times of the year might also ﬁnd a niche, for example,
probiotics to reduce the duration, symptoms and signs of allergy.
Given that claims are permitted on over-the-counter medications,
it may be feasible to allow food labels to indicate that consumption
of certain probiotic yoghurt prior to and during the allergy season
might be beneﬁcial. This is the approach taken by vaccine com-
panies that deliver small amounts of an allergen, such as pollen, pet
dander or mould, twice weekly for several months, followed by a
less frequent maintenance dose. In a pilot study, we selected pro-
biotic strains based upon their in vitro effects at countering allergic
immune parameters (Koyama et al., 2010), and their ability to be
formulated into a yoghurt delivery vehicle. One Biﬁdobacterium
adolescentis isolate had never been used in yoghurt, but it was
added because of its anti-allergic properties. The yoghurt was well
tolerated by the subjects, and although it did not have a statistically
signiﬁcant effect on allergy-related quality of life scores, use of
antihistamines, or eosinophil cationic protein concentration in
nasal lavage in this small study, it did signiﬁcantly increase serum
IL-10 and IL-12 levels during grass allergy season and TGF-b levels
during ragweed season. While a larger sample size is needed to
prove cause and effect, these small studies can provide useful in-
formation to identify potential responders, as long as conclusions
are not over-drawn (Hackshaw, 2008).
Further evidence of the potential for probiotics to improve
quality of life in allergy patients comes from a double-blind, pla-
cebo-controlled, randomized trial in which L. paracasei subsp.
paracasei LP-33 was given to patients with allergic rhinitis who
were already being treated with anti-histidine loratadine (Costa
et al., 2014). The study showed consistently improved ocular
symptoms, but the lack of effect on nasal symptoms, also found in
another probiotic study (Ivory et al., 2013), indicates that preven-
tion and treatment of allergy may need different approaches, with
perhaps ingested probiotics to target systemic anti-inﬂammatory
effects and delay the occurrence of allergic symptoms (Tamura
et al., 2007), and locally-administered probiotics to affect the
nasal passage.
A further potential seasonal approach to probiotics comes from
studies showing that fermented milk can reduce the risk and dura-
tion of the common cold (Guillemard, Tondu, Lacoin, &
Schrezenmeir, 2010; Makino et al., 2010). Could such products be
sold speciﬁcally fromNovember toApril in theNorthernHemisphere
(http://www.cdc.gov/ﬂu/about/season/ﬂu-season.htm) (M€akel€a
et al., 1998) and May to July (http://www.who.int/inﬂuenza/
surveillance_monitoring/2011_GIP_surveillance_seasonal_review/
en/) in the Southern Hemisphere when colds are particularly prev-
alent? A randomized, double-blinded, placebo-controlled 28-wk
intervention study showed that children receiving Lactobacillus
rhamnosus GG supplemented milk had fewer days with respiratory
symptoms than the control group (Kumpu et al., 2013). Interestingly,
the probiotic intervention did not reduce the times that viruses
infected; however, in another Finnish study using a chewable pro-
biotic tablet with L. rhamnosus GG plus Biﬁdobacterium animalis ssp.
lactis BB-12, there was decreased presence of picornaviruses after 3
months (Lehtoranta et al., 2014). In terms of how a probiotic could
interferewith viral infection, a study of 84men andwomen engaged
in winter endurance-based physical activities, showed that regular
ingestion of Lactobacillus casei Shirota fermented milk reduced the
frequency of upper respiratory tract infections, possibly via
increasing salivary IgA levels (Gleeson, Bishop, Oliveira, & Tauler,
2011). Although difﬁcult to prove, the implication is that the anti-
body in the mouth and throat might neutralize the virus before it
reaches the lungs. This is supportedbystudies showing thatprobiotic
food can enhancemucosal immunity to better eradicate the common
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incidence (Groeger et al., 2013; Leyer, Li, Mubasher, Reifer, &
Ouwehand, 2009).
If a company simply wanted to re-brand a slightly different
version of a popular Product X, by reﬁning the content and labelling
as the ‘Cold’ Brand X, this might be allowed, even if speciﬁc disease
claims were not permitted. There is certainly a market niche, as
shown by a product called Cold-fX derived from the roots of North
American ginseng (Panax quinquefolius) that Health Canada's
Natural Health Product Directorate approved to “help reduce the
frequency, severity and duration of cold and ﬂu symptoms by
boosting the immune system”. With an over-the-counter cold
remedy market worth $8 billion in the USA alone (http://www.
ibisworld.com/industry/cough-cold-medicine-manufacturing-otc.
html), dairy probiotics that alleviate colds are worthy of pursuit.
The intent of these examples is to suggest that some probiotics
could target speciﬁc conditions, and still be safe for all who use
them only as a food. Yoghurt production lines can easily accom-
modate different batches, and the distribution networks are in
place in developed countries, with relatively short shelf-life turn-
arounds capable of this targeted use. Current regulatory systems
were set up long ago to restrict disease treatment and prevention
only to drugs, a dogma that needs a radical overhaul, so it would
not be possible for such food products tomake speciﬁc niche claims
in many countries. However, consumer knowledge is acquired from
many sources, in particular the internet and medical science ex-
perts, and dissemination of clinical studies showing such effects
could well drive uptake of the given products. As scientists, it be-
hoves us to educate the public on why scientiﬁc studies apply to
products.
3. Modiﬁcation of dairy probiotic formulations
The modiﬁcation of an existing product is already commonly
done through changes to ﬂavour and packaging or addition of
fruits, such as prunes for intestinal transit and pomegranate with
anti-oxidant or other health beneﬁts. A recent study showed that
ﬂavours can alter the genes expressed by probiotic yoghurt or-
ganisms (Bisanz, Macklaim, Gloor, & Reid, 2014b), suggesting that a
new version of a product that uses a different ﬂavour may have
altered probiotic effects (King et al., 2014). For example, if a natural
non-ﬂavoured yoghurt improves digestion of lactose, a claim
approved by EFSA, could the effect be altered in the presence of
certain fruit additives and does this need to be tested? The impli-
cations that all food variations need to be re-tested would have
signiﬁcant implications for the dairy industry and regulators.
Of all the beneﬁts accrued by probiotics, arguably their effect on
preventing and reducing the duration of diarrhoea, including
antibiotic-associated, has been the most documented (Goldenberg
et al., 2013; Pattani, Palda, Hwang,& Shah, 2013; Szajewska, Skorka,
Ruszczynski,& Gieruszczak-Białek, 2013). Contaminated food alone
contributes to over 1.5 billion cases of diarrhoea in children each
year, resulting in more than three million premature deaths, ac-
cording to the World Health Organization (WHO). As dairy foods
are less easy to transport between countries where diarrhoea rates
are high, this niche has not been targeted by the dairy industry. But,
if probiotic dairy products could be dried and packaged or strains
delivered to allow household propagation, the probiotic organism's
anti-diarrhoeal attributes might reduce morbidity and even mor-
tality associated with diarrhoea. For this to occur, dairy companies
would not only have to dry-powder their products, but also develop
networks to appropriately retain bacterial viability over time and in
different climates. Sachet and stick forms of probiotics are already
sold, and large volumes of skim milk are dried and sold as powder,
so the creation of dried probiotic and dried fermented milk isfeasible. Certainly, the methodologies exist to achieve this (Bauer,
Schneider, Behr, Kulozik, & Foerst, 2012; Fonseca, Cenard, &
Passot, 2015; Huq, Khan, Khan, Riedl, & Lacroix, 2013).
4. Diet-based products
With tens of billions of dollar spent in the USA alone onweight-
loss programs, including drugs and surgeries, and no clinically
proven regimen that guarantees success (http://abcnews.go.com/
Health/100-million-dieters-20-billion-weight-loss-industry/story?
id¼16297197), is there an opportunity for fermented dairy pro-
biotic products for obesity? Studies emerging from the Human
Microbiome Project have suggested that the gut microbiota of
obese individuals differs in composition and/or functionality from
that of people who are able to remain lean (Turnbaugh et al., 2009;
Vrieze et al., 2010). This implies that obesity is not simply explained
by nutritional habits and the reduction of energy expenditure
through decreased physical activity, but to a large extent by the
organisms in the gut. This has resulted in multiple studies aimed at
manipulating these organisms, through intake of prebiotics, pro-
biotics or speciﬁc nutrients, or indeed cessation of products such as
artiﬁcial sweeteners that induce glucose intolerance (Suez et al.,
2014).
A particularly interesting intervention was tested in Finland, in
which 159 womenwere randomized and double-blinded to receive
L. rhamnosus GG or placebo four weeks before expected delivery
and postnatally for 6 months (Luoto, Kalliom€aki, Laitinen, &
Isolauri, 2010). Anthropometric measurements of the children
showed that the perinatal probiotic treatment moderated the
initial phase of excessive weight gain, especially among children
who later became overweight, but it did not affect the second phase
of excessive weight gain at age four. This is intriguing as it suggests
a potential to program the extent of weight gain.
Some critics have used the weight gain acquired by treatment of
livestock as evidence that bacteria, such as Lactobacillus acidophilus
used in some probiotic products, cause obesity (Million et al., 2012),
but there is no such evidence in humans nor any rationale for this to
happen (Delzenne& Reid, 2009). In particular, there is no genetic or
functional reason for one species of Lactobacillus to make people
obese, while other species do not. Indeed, ingestion of probiotic
yoghurt made using L. acidophilus La5 and Biﬁdobacterium lactis
Bb12 was found to improve total cholesterol and LDL-C concen-
trations in a randomized double-blind controlled trial of 60 subjects
with type 2 diabetes and low-density lipoprotein cholesterol (LDL-
C) greater than 2.6 mmol L1 (Ejtahed et al., 2011). Another study
showed that probiotic therapy enhanced the effect of metformin in
reducing the body mass index (Shavakhi et al., 2013) and one
showed it could induceweight loss inwomen (Sanchez et al., 2014).
While experiments in mice show promise for the use of Biﬁdo-
bacterium breve B-3 in skim milk suppressing the accumulation of
body weight and epididymal fat, and improving serum levels of
total cholesterol, fasting glucose and insulin (Kondo et al., 2010), it
is difﬁcult to correlate this with what happens in humans.
A recent human study suggested that the genetic make-up of an
individual can support bacteria, such as Christensenellaceae, and
thereby promote a lean ﬁgure (Goodrich et al., 2014). This led to the
hypothesis that using such a species as a probiotic might alter
metabolism and reduce obesity. In a host that is not receptive to
this species, perhaps the continual passage of the organism through
the gut as a daily probiotic might still confer the desired metabolic
outcome. Of course, for such a dairy application, this depends on
whether or not these spore-formers could be added safely to milk
products, when other spore-forming organisms are infamous for
spoilage and causing illness through toxin production (Doyle et al.,
2014).
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obesity, and may be promoted by bacterial endotoxins that induce
steatohepatitis. Encouraging animal studies have led to clinical
investigation into probiotics for this disease (Eslamparast et al.,
2014). A small study suggested that children already suffering
fromNAFLDmight be aided by 8 strain probiotic VSL#3 intake (Alisi
et al., 2014). That product is sold as a dried, high concentration
sachet rather than in a dairy carrier, but the potential of the
approach working in humans is worthy of further pursuit.
The preliminary ﬁnding that prebiotic inulin/oligofructose can
decrease fat mass in obese women, apparently by increasing gut
Biﬁdobacterium and Faecalibacterium prausnitzii (Dewulf et al.,
2013), is relevant to the dairy ﬁeld as this mix could be added to
fermentedmilk and delivered as a synbiotic. This would be easier in
terms of product development and regulatory approval than having
an organism like F. prausnitzii which has no history of safe use in
humans, scaled-up commercially as a supplement. One recent trial
of 97 children aged 7e18 y, who were overweight and obese (BMI
>85th percentile) and randomly assigned to receive placebo
(maltodextrin) or oligofructose for 12 weeks, did not ﬁnd loss of
weight or body fat (Liber & Szajewska, 2014). Nevertheless, the
potential for prebiotics to reduce weight gain and increase weight
loss by targeting particular gut microbes is worthy of investigation.
5. Probiotic products sold through social businesses
One of the major road blocks to increasing the global impact of
dairy probiotics is a failure to reach billions of people in the
developing world. There are several reasons for this, including
affordability and availability. Milk production is low in much of
Africa and South East Asia, where a large number of people reside
and major health issues of malnutrition, stunting, infectious dis-
eases, and maternal and infant mortality are high. In countries like
India, where milk is available, and often fermented in households,
the protective effect of the yoghurt against chronic diarrhoea de-
pends on the strains used, the dose taken, and the extent of
exposure to pathogens. If the Dahi products consumed contain
Lactococcus lactis ssp. lactis, Lactococcus lactis ssp. cremoris and
Leuconostoc mesenteroides ssp. cremoris, it may provide some pro-
tection (Agarwal & Bhasin, 2002), even though these strains are
more noted for conferring ﬂavour than interfering with entero-
pathogenic bacteria.
Use of highly documented probiotic strains such as L. rhamnosus
GG and L. casei Shirota have been shown to be effective in pre-
venting and controlling diarrhoea in developing countries (Basu,
Paul, Ganguly, Chatterjee, & Chandra, 2009; Oberhelman et al.,
1998; Sur et al., 2011). But until recently, both strains were pro-
tected intellectual property and not available in these countries,
and if they were to be sold, the price would likely be well outwith
the means of the people who needed them the most. This raises an
ethical question of performing such clinical studies then not mak-
ing an efﬁcacious product available upon its completion.
One solution is to use a generic version of L. rhamnosus GG (Kort
& Sybesma, 2012). A 1 gram sachet with the probiotic and a
Streptococcus thermophilus strain is capable of producing 10e100 L
fermented milk per batch. The S. thermophilus strain replaces the
traditional L. delbreuckii ssp. bulgaricus.
With a break-even point at 10 L, including cost of sachet, milk
and labour, there is incentive to produce and market more of this
Yoba yoghurt. Even with shipping, the price point of around
US$0.65 per sachet is competitive with a single tub of yoghurt sold
in retail in Europe. This cost decreases as the number of required
sachets increase. Proﬁts of US$0.30 per litre are reached with 100 L
of sales, which in rural Uganda is a reasonable return. Two thirds of
the yoghurt consumers are regulars and the others incidental. Asmall portion includes children/orphans, so the social business
model is reaching vulnerable subjects and allowing the translation
of dairy research to the consumer. It also delivers health and eco-
nomic beneﬁts to local people. Growth projections are impressive
for such a simple set up.
The Yoba probiotic dairy concept was spurred by a humanitarian
initiative set up in Tanzania in 2004, in which community kitchens
run by women were established to sell L. rhamnosus GR-1 supple-
mented yoghurt. It was assumed that the art of fermentationwould
be widespread, given the history of use in Africa (Anukam & Reid,
2009; Franz et al., 2014). In fact, this was not the case, and few in
the large city of Mwanza, practiced or were aware of how to
ferment milk. These Mwanza and Ugandan dairy groups now feeds
around 15,000 people each day, illustrating the tremendous po-
tential of social business. There have been numerous positive out-
comes including reduction in diarrhoea, rashes and side effects of
drug therapy, and in some cases improvements in CD counts in HIV
patients (Bisanz et al., 2014a; Dols et al., 2011; Hummelen et al.,
2011a, b; Irvine et al., 2010; Irvine, Hummelen, & Hekmat, 2011;
Reid, Gough, Enos, & Reid, 2013; Whaling et al., 2011).
It is not traditional practice for dairy companies to target
amelioration of diseases, mostly because regulatory agencies set up
in the past century state that only drugs can prevent, treat or cure
disease. Indeed, recent unfathomable policy decisions in the US and
Europe have been backward in their approach to probiotics. The
development of new probiotic dairy-based foods to counter infec-
tious and other diseases afﬂicting billions of people and for whom
alternative treatment and prevention regimens are ineffective, too
expensive or unavailable, could include helping to reduce side ef-
fects of drugs (Zhu et al., 2014), competing with pathogens (Corr,
Hill, & Gahan, 2009; Das & Goyal, 2014), enhancing host immune
responses to disease (Foligne et al., 2010; Madsen, 2006), or
providing microbes and metabolites that restore and retain
homoeostasis (Rehman et al., 2012). Although claims may not be
permitted on the product labels, the scientiﬁc results will be pub-
lished and through traditional and social media, consumers will
hear about the results and create a pull for the products. As long as
the messaging is consistent with the quality of the studies, pro-
biotic dairy foods could certainly be promoted more widely to
reduce (Adegboye et al., 2012; O'Connor et al., 2014; Sonedstedt
et al., 2011) and help treat (Camﬁeld, Owen, Scholey, Pipingas, &
Stough, 2011; King et al., 2014) important diseases.
Not all climates are suitable for cows, and therefore milk from
goats, camels and buffalo is used by many people. This has been
part of traditional food for centuries in areas of the developing
world, produced and consumed within households and sold in
small quantities in local markets. However, coordination of milk to
central processing sites then distribution via cold chains to
expansive rural and urban communities either does not occur or is
not well-coordinated. With the income per capita too low to sup-
port large sales of branded yoghurts and cheeses that are typically
sold in Western and Northern countries or South Africa, dairy
probiotics must be affordable to all. For example, Zambia has the
highest poverty ratio of 86% and is the poorest country in theworld,
with seven out of ten people living on less than two dollars a day,
and an average life expectancy of 51 years (http://www.presscave.
com/top-poorest-countries-in-the-world/). If it could better orga-
nize milk centralization (Mumba, Pandey, & van der Jagt, 2013) it
would have the potential to establish a mechanism to produce and
disseminate probiotic dairy foods.
In short, dairy science has made many important advances that
have led to foods with highly nutritional, health-conferring prop-
erties. However, until people in greatest need of such products gain
access, we will have collectively failed in our translational
endeavours.
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The ﬁnal area of discussion that has great potential for dairy
probiotics is in detoxiﬁcation of environmental pollutants. With
many deaths worldwide associated with water, air and soil pollu-
tion (Song, Christiani, Wang, & Ren, 2014), and anthropomorphic
activity increasing levels of toxins, such as heavy metals and pes-
ticides in the environment (Muir et al., 2009), efforts are needed to
prevent adsorption of these compounds into the body of humans
and animals. The toxins, adsorbed acutely or via chronic long term
exposure, can affect neurological and cognitive development in
children and immune and cardiovascular diseases (Karagas et al.,
2012).
The detoxiﬁcation potential for dairy probiotics comes from the
ﬁnding that lactic acid bacteria have an afﬁnity for many toxic
metals and various organic pesticides, making it possible to
sequester them prior to their adsorption into the bloodstream and
tissues. The most recent and encouraging evidence for this comes
from a recent study undertaken in Tanzania. The 30 million people
living on Lake Victoria already face major challenges with HIV,
malaria, poverty, malnutrition and violence, but added to that they
are exposed to high levels of environmental pollutants. Admittedly,
the 40 million people living around the Great Lakes of North
America are exposed to equally high levels of mercury, while
populations in China and India face exposure to a variety of toxic
compounds. Unfortunately, while North Americans can choose to
avoid eating products of the Great Lakes, people living around Lake
Victoria cannot and ﬁsh consumption is part of their staple diet. So,
although this is far from being an African problem alone, it was
decided to study the ability of probiotic yoghurt to sequester heavy
metals, following in vitro studies showing this indeed was feasible
(Monachese, Burton, & Reid, 2012). The ﬁnding of excessive levels
of heavy metals in the bloodstream of the Mwanza children
compared with Canadian children demonstrated the gravity of the
pollution (Bisanz et al., 2014a). The reduction in further adsorption
of mercury and arsenic after one month of ﬁve days per week
consumption of probiotic yoghurt was encouraging, albeit not
reaching statistical signiﬁcance. However, three month treatment
of pregnant women did show signiﬁcantly reduced levels of mer-
cury and arsenic uptake. The mechanism involves the binding of
the lactobacilli to the metals, as shown by various microscopy
techniques. The research has also identiﬁed mercury reductase
genes as a potential means to further reduce mercury adsorption.
This is a new area of application for dairy science, but other
examples exist in countering environmental pollutants. One study,
notably from China, has shown that fermented skimmed milk
accelerated degradation of organophosphorus pesticides chlor-
pyrifos, diazinon, fenitrothion, malathion and methyl parathion, in
part due to phosphatase production by the lactic acid bacteria
(Zhang, Xu, Liu, & Zhao, 2014). This is interesting not only because
of the high use of pesticides in China, but because the dairy market,
especially milk and yoghurt, has grown substantially. With pastures
at a premium, oil prices ﬂuctuating, and cost of feed escalating, new
models are needed to help dairy markets continue to grow.
Another example is the ability of lactobacilli to bind to myco-
toxins produced by Aspergillus species in pre- or post-harvest ce-
reals and milk (Hamidi et al., 2013). When tested in humans, a
statistically signiﬁcant decrease in urinary concentration occurred
when probiotics were consumed twice daily for ﬁve weeks (El-
Nezami et al., 2006). A staggering 4.5 billion people living in
developing countries are estimated to be chronically exposed to
largely uncontrolled amounts of the toxins (Williams et al., 2004).
This exposure signiﬁcant increases the risk of liver cancer. With
in vitro data showing that L. rhamnosus GG reduces aﬂatoxin B1
transport, metabolism and toxicity to intestinal cells (Gratz et al.,2007), the Yoba generic version of this strain in probiotic yoghurt
could prove effective in high aﬂatoxin contaminated areas of east
Africa.
7. What represents sufﬁcient evidence?
The concept of probiotics is not without its critics, and the
insufﬁciency of clinical trial data, or failings of some study designs
are often cited as evidence that probiotics have not been proven to
impact human health. Such a topic may warrant a separate review,
but some points are worthy of note. It is unreasonable to suggest
that naturally occurring food grade bacteria delivered as supple-
ment or food need to be tested to the same extent as novel syn-
thetic chemicals being considered as drugs. Nevertheless, the FDA
itself states in relation to drug approvals, “in some cases, FDA has
relied on pertinent information from other adequate and well-
controlled studies of a drug, such as studies of other doses and
regimens, of other dosage forms, in other stages of disease, in other
populations, and of different endpoints, to support a single
adequate and well-controlled study demonstrating effectiveness of
a new use”, and “In other cases, FDA has relied on only a single
adequate and well-controlled efﬁcacy study to support approval”
(FDA, 1998). Still, many drugs are approved with insufﬁcient evi-
dence, as shown in a European study of 200 unique newmedicines,
161 standard and 39 orphan medicines, approved by the European
Medicines Agency, where the median total number of patients
studied before approval was 1708 for the former and 438 for the
latter, insufﬁcient to evaluate safety and long-term efﬁcacy
(Duijnhoven et al., 2013). In short, there is no magic bullet for
proving efﬁcacy, and all products developed for human use should
be continually monitored and tested. Probiotics are, for the most
part, not even attempting to claim efﬁcacy, so the fact that clinical
trials (many of which have been cited here) have been performed in
randomized, placebo-controlled fashionwith hundreds of subjects,
is laudable. Critics may not be convinced even by themeta-analyses
cited here and elsewhere. Guidelines that provide a third party
assessment of the volume of documentation and levels of evidence
at least help guide consumers in choosing which probiotic may
beneﬁt them (Skokovic-Sunjic, 2014). In truth, patients have long
relied on healthcare professionals providing themwith such advice
on drugs, and that process is far from perfect (Velo&Minuz, 2009).
The most important point is that all products using the term
probiotic should have undergone scientiﬁc rigor, be produced to the
highest standards possible particularly if used for vulnerable sub-
jects, and be tested in humans as best as is practical and possible.
Studies of 20e500 subjects should not be discouraged simply
because of size; all studies can reveal useful information. But over-
stating effectiveness does not advance the credibility of the ﬁeld.
8. Conclusions
Many challenges face the dairy industry worldwide. Tradition-
ally strong markets in Europe have been adversely affected by
politically motivated legislation, rising production costs and trends
towards organic and ‘natural’ foods. Nevertheless, the globalization
of food distribution provides new opportunities, not the least of
which are markets in the Middle East and Asia where per capita
income can support the purchase of high end dairy products, and
there is a custom of eating fermented milk products (Chilton,
Burton, & Reid, 2015). The beneﬁts that lactic acid bacteria have
provided throughout human evolution need to be re-invigorated
through research, development and application. The probiotic
market is witnessing unprecedented growth, and the application to
dairy products has the potential to improve the lives of millions of
people worldwide.
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